We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates
Read MoreHide Full Article
Intuitive Surgical, Inc. (ISRG - Free Report) reported first-quarter 2021 adjusted earnings per share (EPS) of $3.52, which beat the Zacks Consensus Estimate of $2.61 by 34.9%. Moreover, the bottom line improved 30.9% year over year.
Revenue Details
The Zacks Rank #2 (Buy) company reported revenues of $1.29 billion, which surged 17.5% from the prior-year quarter. The top line also outpaced the Zacks Consensus Estimate by 16.2%.
Segment Details
Instruments & Accessories
Revenues at the segment amounted to $706 million, reflecting year-over-year improvement of 14%. This can be attributed to 16% growth in da Vinci procedure volume.
Systems
In the reported quarter, System revenues surged 30% year over year to $369 million. In fact, the company shipped 298 da Vinci Surgical Systems in the quarter, compared to 237 systems in the prior-year quarter.
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise
Services revenues were $217.5 million, up 9.5% from the year-ago quarter.
Outside the United States, revenues totaled $444.6 million, up 39.8% on a year-over-year basis.
Outside the United States, Intuitive Surgical placed 108 systems in the first quarter compared with 55 in the prior-year quarter. Of these, 59 were in Europe, eight in Japan and 23 in China.
Margins
Adjusted gross profit in the reported quarter was $927.8 million, up 21.1% year over year. As a percentage of revenues, gross margin in the quarter was 71.8%, up 210 basis points (bps).
Adjusted operating income totaled $527.3 million, up 37.2% year over year. As a percentage of revenues, operating margin in the quarter was 40.8%, up 580 bps.
Financial Position
The company exited the first quarter with cash, cash equivalents and investments of $7.23 billion, compared with $6.87 billion in the previous quarter.
Total assets were $11.54 billion, compared with $11.17 billion sequentially.
Outlook
Due to persistent uncertainty surrounding the extent and duration of the pandemic, and the timing of global recovery and economic normalization; the company cannot ascertain the future impact on its operations and financial performance during this time. Consequently, the company has refrained from issuing any guidance for 2021.
Wrapping Up
Intuitive Surgical ended the first quarter on a solid note. The company displayed strong segmental performance in the quarter under review. Moreover, the company witnessed growth in da Vinci procedure volume in the quarter under review. Expansion in both gross and operating margins is a positive. Also, overall international sales improved in the quarter.
However, intense competition in the global MedTech space remains a concern.
DENTSPLY SIRONA is set to release results on May 6. The Zacks Consensus Estimate for DENTSPLY SIRONA’s first-quarter 2021 adjusted EPS is currently pegged at 55 cents. The consensus mark for first-quarter revenues stands at $923.3 million.
The Zacks Consensus Estimate for Integra LifeSciences’ first-quarter 2021 adjusted EPS is currently pegged at 56 cents. The consensus estimate for first-quarter revenues stands at $349.9 million.
The Zacks Consensus Estimate for Align Technology’s first-quarter 2021 adjusted EPS is currently pegged at $1.94. The consensus estimate for revenues stands at $806.4 million.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates
Intuitive Surgical, Inc. (ISRG - Free Report) reported first-quarter 2021 adjusted earnings per share (EPS) of $3.52, which beat the Zacks Consensus Estimate of $2.61 by 34.9%. Moreover, the bottom line improved 30.9% year over year.
Revenue Details
The Zacks Rank #2 (Buy) company reported revenues of $1.29 billion, which surged 17.5% from the prior-year quarter. The top line also outpaced the Zacks Consensus Estimate by 16.2%.
Segment Details
Instruments & Accessories
Revenues at the segment amounted to $706 million, reflecting year-over-year improvement of 14%. This can be attributed to 16% growth in da Vinci procedure volume.
Systems
In the reported quarter, System revenues surged 30% year over year to $369 million. In fact, the company shipped 298 da Vinci Surgical Systems in the quarter, compared to 237 systems in the prior-year quarter.
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise
Intuitive Surgical, Inc. price-consensus-eps-surprise-chart | Intuitive Surgical, Inc. Quote
Services
Services revenues were $217.5 million, up 9.5% from the year-ago quarter.
Outside the United States, revenues totaled $444.6 million, up 39.8% on a year-over-year basis.
Outside the United States, Intuitive Surgical placed 108 systems in the first quarter compared with 55 in the prior-year quarter. Of these, 59 were in Europe, eight in Japan and 23 in China.
Margins
Adjusted gross profit in the reported quarter was $927.8 million, up 21.1% year over year. As a percentage of revenues, gross margin in the quarter was 71.8%, up 210 basis points (bps).
Adjusted operating income totaled $527.3 million, up 37.2% year over year. As a percentage of revenues, operating margin in the quarter was 40.8%, up 580 bps.
Financial Position
The company exited the first quarter with cash, cash equivalents and investments of $7.23 billion, compared with $6.87 billion in the previous quarter.
Total assets were $11.54 billion, compared with $11.17 billion sequentially.
Outlook
Due to persistent uncertainty surrounding the extent and duration of the pandemic, and the timing of global recovery and economic normalization; the company cannot ascertain the future impact on its operations and financial performance during this time. Consequently, the company has refrained from issuing any guidance for 2021.
Wrapping Up
Intuitive Surgical ended the first quarter on a solid note. The company displayed strong segmental performance in the quarter under review. Moreover, the company witnessed growth in da Vinci procedure volume in the quarter under review. Expansion in both gross and operating margins is a positive. Also, overall international sales improved in the quarter.
However, intense competition in the global MedTech space remains a concern.
Other Key Picks
Some other top-ranked stocks, which are expected to report earnings soon, are DENTSPLY SIRONA Inc. (XRAY - Free Report) , Integra LifeSciences Holdings Corporation (IART - Free Report) and Align Technology, Inc. (ALGN - Free Report) , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
DENTSPLY SIRONA is set to release results on May 6. The Zacks Consensus Estimate for DENTSPLY SIRONA’s first-quarter 2021 adjusted EPS is currently pegged at 55 cents. The consensus mark for first-quarter revenues stands at $923.3 million.
The Zacks Consensus Estimate for Integra LifeSciences’ first-quarter 2021 adjusted EPS is currently pegged at 56 cents. The consensus estimate for first-quarter revenues stands at $349.9 million.
The Zacks Consensus Estimate for Align Technology’s first-quarter 2021 adjusted EPS is currently pegged at $1.94. The consensus estimate for revenues stands at $806.4 million.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>